GLP-1 drugs and gallstones: the real risk, why it happens, and what to watch (2026)

The short version

GLP-1 medications (semaglutide, tirzepatide, liraglutide) modestly raise the risk of gallstones and gallbladder disease, and the risk is highest in people using them for weight loss, at higher doses, and over longer periods. It is uncommon, but the one symptom not to ignore is steady pain in the upper right abdomen. This page explains the real numbers, who is most at risk, why it happens, how it is diagnosed and treated, and what you can do to lower the odds.

What the evidence actually shows

The strongest data is a 2022 systematic review and meta-analysis in JAMA Internal Medicine that pooled 76 randomized controlled trials and 103,371 patients. Randomization to a GLP-1 receptor agonist was associated with a higher risk of gallbladder or biliary disease — relative risk 1.37 (95% CI, 1.23-1.52) [1].

Breaking it down: cholelithiasis (gallstones) relative risk 1.27, cholecystitis (gallbladder inflammation) 1.36, and biliary disease 1.55. Critically, the risk depended on context — in trials using GLP-1s for weight loss it was more than double (relative risk 2.29; 95% CI, 1.64-3.18), versus 1.27 in diabetes trials [1].

Two dose-and-time patterns stood out and matter for how you use the drug: risk was higher at higher doses (RR 1.56 vs no meaningful increase at lower doses) and with longer duration of use (RR 1.40) [1]. Gallbladder disease is also listed in the FDA prescribing information for these drugs, so it is a recognized, labeled effect, not a fringe concern [2].

Why it happens: two mechanisms stack

The first mechanism is the weight loss itself. Rapid weight loss is a long-established gallstone risk factor — it shifts the cholesterol-to-bile-salt balance in bile and promotes stone formation, no matter how the weight comes off. Crash diets and bariatric surgery raise gallstone risk for exactly the same reason. GLP-1 drugs cause substantial, sometimes fast weight loss, so they inherit that risk [1].

The second is direct: GLP-1 signaling slows gallbladder emptying. The gallbladder's job is to contract and squirt bile into the intestine when you eat fat; when it contracts less, bile sits and concentrates, and concentrated, stagnant bile is more likely to crystallize into stones. That the meta-analysis found the highest risk at higher doses, longer durations, and in weight-loss trials fits both mechanisms neatly — more drug effect on the gallbladder plus more cumulative weight loss over time [1].

Who is at highest risk

The risk is not evenly distributed. On top of the drug- and dose-related factors above, the classic gallstone risk factors still apply and add up: being female, older age, a family history of gallstones, pregnancy history, and pre-existing gallstones or 'sludge' on a prior scan. Someone with several of these who is also losing weight quickly on a high dose is at the higher end of the range [1].

The single most modifiable factor is the pace of weight loss. The faster you lose, the more the bile chemistry shifts — which is why a large, rapid drop (the very thing the strongest drugs and doses produce) carries more gallstone risk than a slower, steadier decline to the same endpoint. That does not mean avoiding effective treatment; it means the pace and dose are worth discussing if you already carry gallstone risk factors.

Warning signs and what to do

Know the picture of a gallbladder attack (biliary colic): steady, often severe pain in the upper right abdomen or just below the breastbone, frequently starting within an hour of a fatty meal, lasting from 30 minutes to several hours, and sometimes radiating to the right shoulder blade, with nausea or vomiting [1][2].

Certain features signal something more serious than a simple attack and need urgent care: fever or chills (a sign of infection, cholecystitis), jaundice — yellowing of the skin or the whites of the eyes — or dark urine with pale stools, which point to a stone blocking the bile duct. These are not wait-and-see symptoms [1][2].

Gallstones vs pancreatitis: telling them apart

GLP-1 labels carry a separate caution for pancreatitis, and its symptoms overlap with gallbladder disease, which is why sudden severe upper-abdominal pain on a GLP-1 always deserves prompt evaluation rather than home management. The two are related: a gallstone that blocks the shared drainage duct can actually trigger pancreatitis (gallstone pancreatitis).

As a rough guide, gallbladder pain tends to sit in the upper right and can radiate to the right shoulder, while classic pancreatitis pain sits in the upper middle abdomen and bores straight through to the back, often with persistent vomiting. But you should not try to diagnose which one it is yourself — both need a clinician, and the workup (bloodwork plus imaging) is what tells them apart. The takeaway is simple: severe, persistent upper-abdominal pain is a call-now symptom either way.

How it's diagnosed and treated

Diagnosis usually starts with an abdominal ultrasound, which is quick, radiation-free, and good at spotting gallstones and an inflamed gallbladder wall; blood tests check for infection and bile-duct blockage, and sometimes further imaging follows. Many gallstones are 'silent' — found incidentally and never causing trouble — and those typically need no treatment.

When stones cause repeated attacks or complications like cholecystitis, the standard treatment is surgical removal of the gallbladder (cholecystectomy), usually done laparoscopically as a common, low-risk procedure; you can live normally without a gallbladder. Ursodeoxycholic acid, a bile-acid medication, can dissolve some small cholesterol stones slowly and is also used preventively during rapid weight loss, but it is not a substitute for surgery once stones cause real problems. Which path fits depends on your symptoms and imaging — a clinician's call.

Lowering your risk

You can't remove the risk, but you can shrink it. A steadier weight-loss pace is protective, since very rapid loss is the larger driver — one more reason not to push doses faster than your tolerance and plan call for. Staying well hydrated and eating regular meals with some dietary fat (rather than fasting for long stretches or eating near-zero-fat) actually helps, because it prompts the gallbladder to contract and empty instead of letting bile stagnate.

For higher-risk patients undergoing rapid weight loss, some clinicians prescribe ursodeoxycholic acid, which is shown to reduce gallstone formation during rapid weight loss — but that is an individualized prescriber decision, not a self-treatment. The universal move is simpler and free: report upper-right abdominal pain promptly instead of assuming it is ordinary GLP-1 nausea.

Do you have to stop the GLP-1?

Not necessarily. A single mild, self-resolving episode of biliary colic is not an automatic reason to abandon an effective medication — it is a reason to be evaluated and to talk with your prescriber about pace and dose. Confirmed cholecystitis, a blocked duct, or gallstone pancreatitis is a different matter and may mean pausing the drug and treating the gallbladder first, sometimes surgically.

This is a genuinely individual decision that weighs the benefit you're getting from the drug against the severity of the gallbladder problem. What it should never be is a decision made silently at home by pushing through severe pain. Loop in your clinician, get the imaging, and decide from there.